Seattle Genetics, the Bothell, WA-based maker of cancer drugs, said today it has started a final-stage clinical trial of SGN-35 in patients with relapsed forms of Hodgkin’s disease. The drug is an “empowered antibody” that combines the tumor-targeting ability of an antibody with a toxin to give it more kick. It will be studied in 100 patients who get a dose every three weeks, with a primary goal of showing tumor shrinkage.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
